Kyowa Kirin Co.,Ltd. Logo

Kyowa Kirin Co.,Ltd.

A specialty pharmaceutical company focused on oncology, nephrology, and immunology.

4151 | T

Overview

Corporate Details

ISIN(s):
JP3256000005
LEI:
Country:
Japan
Address:
千代田区大手町一丁目9番2号

Description

Kyowa Kirin is a global specialty pharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative medicines. Leveraging advanced biotechnology and expertise in antibody engineering, the company is dedicated to addressing unmet medical needs. Its primary focus is on creating novel treatments in therapeutic areas such as oncology, nephrology, and immunology. Kyowa Kirin is committed to discovering and delivering drugs for complex and rare diseases, aiming to improve the health and well-being of patients worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-09 07:33
確認書
Japanese 8.1 KB
2023-03-09 07:32
有価証券報告書-第100期(2022/01/01-2022/12/31)
Japanese 3.7 MB
2023-03-09 07:32
内部統制報告書-第100期(2022/01/01-2022/12/31)
Japanese 22.4 KB
2022-11-04 07:35
確認書
Japanese 8.2 KB
2022-11-04 07:34
四半期報告書-第100期第3四半期(令和4年7月1日-令和4年9月30日)
Japanese 2.1 MB
2022-08-04 08:33
確認書
Japanese 8.1 KB
2022-08-04 08:32
四半期報告書-第100期第2四半期(令和4年4月1日-令和4年6月30日)
Japanese 1.7 MB
2022-05-10 08:36
四半期報告書-第100期第1四半期(令和4年1月1日-令和4年3月31日)
Japanese 2.1 MB
2022-03-08 07:32
内部統制報告書-第99期(令和3年1月1日-令和3年12月31日)
Japanese 22.5 KB
2022-03-08 07:31
確認書
Japanese 8.1 KB
2022-03-08 07:30
有価証券報告書-第99期(令和3年1月1日-令和3年12月31日)
Japanese 3.2 MB
2021-11-01 07:32
四半期報告書-第99期第3四半期(令和3年7月1日-令和3年9月30日)
Japanese 2.2 MB
2021-08-03 08:35
四半期報告書-第99期第2四半期(令和3年4月1日-令和3年6月30日)
Japanese 2.2 MB
2021-05-06 08:30
四半期報告書-第99期第1四半期(令和3年1月1日-令和3年3月31日)
Japanese 2.2 MB
2021-03-09 07:32
内部統制報告書-第98期(令和2年1月1日-令和2年12月31日)
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all Kyowa Kirin Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kyowa Kirin Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kyowa Kirin Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.